company background image
ADCT

ADC Therapeutics NYSE:ADCT Stock Report

Last Price

US$8.12

Market Cap

US$619.9m

7D

3.3%

1Y

-69.4%

Updated

11 Aug, 2022

Data

Company Financials +
ADCT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ADCT Stock Overview

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.

ADC Therapeutics SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ADC Therapeutics
Historical stock prices
Current Share PriceUS$8.12
52 Week HighUS$32.00
52 Week LowUS$5.52
Beta1.13
1 Month Change-10.87%
3 Month Change9.88%
1 Year Change-69.36%
3 Year Changen/a
5 Year Changen/a
Change since IPO-72.61%

Recent News & Updates

Aug 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

ADC Therapeutics press release (NYSE:ADCT): Q2 Non-GAAP EPS of -$0.73. Revenue of $17.29M (+359.8% Y/Y) misses by $13.93M. “The ZYNLONTA® launch is advancing steadily as we continue to increase awareness and advocacy. There is significant opportunity ahead and we have a focused plan in place to achieve continued growth in the coming quarters,” commented Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “Our pipeline of hematology and solid tumor programs is progressing well with impressive Cami Phase 2 data in Hodgkin lymphoma presented at the EHA Congress in June. Our recent license agreement with Sobi® in Europe gives us worldwide access for ZYNLONTA. We have a strong cash runway extending into early 2025 which makes us well-positioned to execute on our key objectives.”

Jul 21
Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts

Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts

Shareholders in ADC Therapeutics SA ( NYSE:ADCT ) may be thrilled to learn that the analysts have just delivered a...

Shareholder Returns

ADCTUS BiotechsUS Market
7D3.3%4.3%1.2%
1Y-69.4%-22.1%-11.6%

Return vs Industry: ADCT underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: ADCT underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is ADCT's price volatile compared to industry and market?
ADCT volatility
ADCT Average Weekly Movement10.7%
Biotechs Industry Average Movement12.6%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: ADCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ADCT's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011312Ameet Mallikhttps://www.adctherapeutics.com

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.

ADC Therapeutics SA Fundamentals Summary

How do ADC Therapeutics's earnings and revenue compare to its market cap?
ADCT fundamental statistics
Market CapUS$619.86m
Earnings (TTM)-US$186.96m
Revenue (TTM)US$93.95m

6.6x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADCT income statement (TTM)
RevenueUS$93.95m
Cost of RevenueUS$160.21m
Gross Profit-US$66.26m
Other ExpensesUS$120.70m
Earnings-US$186.96m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.43
Gross Margin-70.53%
Net Profit Margin-199.01%
Debt/Equity Ratio269.6%

How did ADCT perform over the long term?

See historical performance and comparison